Introduction
Diamond-Blackfan Anemia (DBA) is a hypoplastic congenital anemia that presents within the first two years of life. 1 In addition to symptoms of anemia, patients display various other symptoms including growth retardation, skeletal deformities, congenital heart defects, mental retardation and/or other abnormalities. [2] [3] [4] [5] Patients show low hemoglobin (Hb) and high fetal hemoglobin (Hb-F) levels, high adenosine deaminase activity (ADA), high mean corpuscular volume (MCV) and the diagnosis is confirmed by bone marrow (BM) examination which typically shows a normal cellularity but few erythroid progenitors. 1, [6] [7] [8] The initial treatment is steroid therapy but patients not responding to steroids require regular transfusions that over time result in lethal tissue iron overload. 1,2 A BM transplantation can cure DBA, 9 but only a fraction of patients have an HLA-matched sibling. Most cases of DBA are sporadic but 10-25% have a positive family history. 4, 10 Twenty five percent of the patients have a mutation in the ribosomal protein S19 (RPS19) gene. 11, 12 We have previously shown that RPS19 gene transfer into BM cells from several RPS19 deficient DBA patients increases the number of erythroid progenitors (BFU-E and CFU-E) 2-3 fold compared to patient cells transduced with a GFP control vector. RPS19 transgene overexpression also improves the erythroid progenitor proliferation defect in RPS19 deficient DBA patient CD34 + cells in vitro. 13, 14 A second DBA locus on chromosome 8p22-p23 shows genetic linkage in 50% of DBA patients but the gene has not been identified yet. 15 The pathophysiological mechanism of the disease remains unknown.
In order to investigate the hematopoietic and molecular mechanisms responsible for pathogenesis in RPS19 deficient DBA, it is essential to develop a suitable model of RPS19 deficiency that allows extensive molecular studies. Recently, Matsson et al. only.
For personal use at PENN STATE UNIVERSITY on February 23, 2013 . bloodjournal.hematologylibrary.org From developed a mouse model with a targeted disruption of the RPS19 gene. 16 The homozygous RPS19-/-mice exhibit an embryonic lethal phenotype prior to placental implantation in mice with C57BL/6J background. Unlike human RPS19-deficient DBA patients, the haploinsufficient RPS19+/-heterozygote mice have normal levels of RPS19 mRNA and display no hematological abnormalities. Collectively, it is clear that novel murine and human model systems for DBA are required to explore the molecular mechanism for the disease, to discover the pathogenesis of the anemia and to develop new therapeutic strategies for the disorder.
Recently, it has been shown that specific knockdown of endogenous genes can be achieved by RNA interference. Permanent, stable expression of small interfering RNAs (siRNAs) that target specific mRNAs for degradation, can be generated with plasmid-or viral vector-based delivery systems. [17] [18] [19] [20] In this study we take advantage of a lentiviral vector system, that we have recently developed where the 3´ longterminal repeat which duplicates during reverse transcription, contains the human polymerase III promoter H1, driving expression of an siRNA hairpin precursor sequence directed against the RPS19 mRNA. 21 Using this system we demonstrate that downregulation of RPS19 mRNA in primary human CD34 + hematopoietic cells significantly impairs erythroid development and mimics defects in erythroid differentiation seen in cells from DBA patients.
Material and Methods
Design and cloning of lentiviral siRNA vectors.
The human RPS19 cDNA sequence (NM_001022) 12 was searched for suitable siRNA target sequences starting with aag followed by 18 nucleotides. The 21nt sense only.
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Northern blot analysis
Total RNA was isolated from GFP + CB cells using TRIzol reagent, as described by the manufacturer (Invitrogen, Carlsbad, California, USA). RNA from each sample was loaded on a 1% agarose gel, transferred onto a Hybond N+ membrane (Amersham Pharmacia, Buckinghamshire, United Kingdom) and hybridized using a full-length human RPS19 probe obtained by digesting the pSkRIGw plasmid with AgeI and EcoRI. The probe was labeled with ( 32 P) dCTP using a random priming kit (Amersham Pharmacia, Buckinghamshire, England). The membrane was washed twice with 2xSSC at 42 0 C, twice with 2xSSC + 1% SDS at 65 0 C and twice with 0.1xSSC + 1% SDS at 65 0 C and subsequently exposed to Kodak x-ray film.
Antibodies and Western blot analysis
The chicken polyclonal anti-RPS19 antibody was derived from eggs immunized with For personal use at PENN STATE UNIVERSITY on February 23, 2013. bloodjournal.hematologylibrary.org From Life Science, Boston, MA) according to the manufacturer's protocol. Densitometry was performed on developed film by using Image J 1.30v software to quantify the data.
Colony assays
After each sorting 2,000 GFP + BM or CB cells transduced with each vector were plated in quadruplicate 35-mm dishes in 1.1 ml of H4230 methylcellulose (Stem Cell
Technologies, Vancouver, BC, Canada) with erythropoietin (5 U/ml) (Epo; JanssenCilag, Sollentuna, Sweden), IL-3 (100 ng/ml) (a gift from Novartis, Basel, Switzerland) and GM-CSF (200 ng/ml) (a gift from Novartis). The cells were cultured at 37°C in a humidified atmosphere with 5% CO 2 . BFU-E and CFU-GM/M were counted on day 14 and the average of the 4 plates was determined. Each colony experiment was repeated 5 times except for the DBA patient cells that were done twice.
Liquid culture assays
In order to assay the developmental potential of RPS19 silenced cells, 2000 CD34 + GFP + BM cells were cultured in 96-well microtiter plates containing medium supporting either erythroid, myeloid or erythroid and myeloid (mixed) differentiation as described before. 23, 24 Erythroid liquid culture medium: IMDM containing FCS (30%), penicillin-streptomycin (100 U/ml) Hydrocortisone (10 -6 M), 2-ME (10 -4 M), Epo (10U/mL), IL-3 (0.01ng/mL) and IL-6 (0.001ng/mL). 24 Myeloid liquid culture medium: X-vivo-15 containing, FCS (20%), penicillin-streptomycin (100 U/ml), SCF (20ng/mL), IL-3 (30ng/mL), G-CSF (100ng/mL). 23 Myelo-erythroid liquid-culture medium: X-vivo-15 containing, FCS (20%), penicillin-streptomycin (100 U/ml), SCF only.
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Image acquisition and manipulation
A Zeiss Axioplan microscope was used with a 20x/0,60 lens. The picture files were pasted in Microsoft® PowerPoint X for Mac®slides and converted to TIFF formated picture files. The figure files were cropped in Adobe Photoshop 6.0 and formated to jpg format.
DAF staining
As described before 2,7-Diaminofluroene (DAF, purchased from Sigma) stains hemoglobin-containing cells blue due to the hemoglobin induced pseudoperoxidase reaction. 25 Microscopically dark blue cells were counted as DAF positive.
Flow cytometric analysis and cell sorting
Cultured CB and BM cells were analyzed by FACS Calibur and CellQuest software (Becton-Dickinson). The CD34, CD33, CD13, CD71, Glycophorin A and CD41
antibodies were purchased from Becton Dickinson. Cells were sorted on the basis of their expression of GFP or CD71/GlyA using a FACS Vantage cell sorter (BectonDickinson). FACS analysis for simultaneous detection of GFP and YFP was performed using special filters as previously described.
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Statistical analysis
only.
Results are expressed as mean values ± Standard error of the mean (SEM).
Comparison among groups was made using the two-tailed nonparametric MannWhitney test.
Results

Effective suppression of RPS19 mRNA and protein by siRNA
In order to study the effects of RPS19 mRNA deficiency in hematopoiesis we asked whether a DBA phenotype could be induced in healthy cells by permanent knockdown of RPS19 mRNA expression using siRNA-expressing lentiviral vectors.
Three siRNA sequences against RPS19 mRNA (RPS19-A, RPS19-B, and RPS19-C) and one scrambled (Scr) control sequence were inserted into a lentiviral construct (pLV-TH), 21 to generate 3 separate siRNA vectors and one control vector ( Figure 1a ). only.
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At 5 days following transduction, the siRNA vectors have generated haploinsufficient levels (40-60% of normal) in the transduced cells (Figure 1 e) . The reduction in RPS19 protein levels reflected the RPS19 mRNA levels and was most pronounced in cells treated with LV-TH-RPS19-C vector and least affected in cells treated with the LV-TH-RPS19-A vector. only.
Impaired erythroid differentiation and proliferation of erythroid progenitors in
RPS19 deficient
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Defects in erythroid development and proliferation can be rescued by RPS19 transgene expression.
In order to confirm that the erythroid defect was specifically caused by RPS19 deficiency we designed a lentiviral vector expressing YFP together with RPS19. To rescue the RPS19 deficiency, the coding sequence of RPS19 was changed so that it codes for the normal amino acid sequence, but is no longer silenced by the LV-TH-RPS19-B vector (Figure 4a ). CD34+ BM cells were transduced with the siRNA vectors and after 2 days sorted for GFP and again transduced with the RPS19-rescuing vector LV-mRIY or the YFP control vector LV-YFP. After 7 days culture in only.
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For Table 2 . In myeloid culture conditions RPS19-silenced cells contained a higher fraction of CD13 positive/high cells (Figure 5c ) showing that even though proliferation is reduced, the myeloid maturation is not arrested.
For Myeloid differentiation is less sensitive than erythroid differentiation to the RPS19 deficiency.
To compare the effects of RPS19 silencing on proliferation and maturation of myeloid only.
Discussion
Since RPS19 is a ubiquitously expressed protein required for efficient translation in all cells, very low RPS19 expression is likely to hamper various cell functions, leading to cell cycle arrest or apoptosis, which is seen in the homozygous RPS19 knockout mice that die prior to implantation. 16 In order to create a valid model for DBA pathogenesis, RPS19 expression must be reduced to levels that induce an erythroid defect without interfering with general cell functions. 14, 34 In a careful in vitro study using peripheral blood cells from DBA patients Ohene-Abuakwa et al. find that the main defect in DBA erythropoiesis is somewhat later (after the Epo triggered onset of erythroid differentiation). 35 However, no erythropoietin was used during the first 7 days of culture and this difference may account for the differences in our and their findings. The hematopoietic system has a great proliferative potential, capable of increasing cell production 5-10 fold with a 2,5 fold higher relative turnover of erythroid cells compared to myeloid cells. Reduced proliferation capacity is a possible explanation to the hematopoietic and developmental defects in DBA. The increased sensitivity to RPS19 silencing during erythroid compared to myeloid differentiation, could be due to an impairment of the translational machinery or a disruption of an unknown extraribosomal function of RPS19. For example, ribosomes lacking RPS19 or containing mutated forms may alter the translation rate constants for transcripts important for erythroid development. An example of this mechanism of translational regulation is the interferon-Gamma induced phosphorylation and release of ribosomal protein L13a which specifically inhibits ceruloplasmin translation. 36 Another possibility is that RPS19 has an extraribosomal function interacting with factors involved in erythropoiesis. RPS19 has been shown to interact with fibroblast growth factor 2 in NIH3T3 cells, 37 and it is possible that RPS19 also interacts with factors in erythroid development.
In order to understand the pathogenesis in DBA it is important to have access to cells in which the pathologic process can be induced and studied. Our model system presented in this paper significantly simplifies future studies on ribosomal and extraribosomal mechanisms involved in RPS19 deficient DBA.
